Skip to content
S10136Senate2025-2026 Session

Cap COVID Antiviral Costs

Official title

“Relates to capping cost sharing for antiviral COVID-19 therapeutics”

Sponsor Erik BottcherSD-47Affects Finance
Status
In Senate Committee
Insurance
Impact
7/10
Significant
Passage
20%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires insurance to cover COVID-19 antiviral medicines with no out-of-pocket costs for patients.

Why it matters

  1. Statewide Impact Across Insurance Types. The bill applies to nearly all forms of health insurance in New York, including individual, group, and public plans like Medicaid—ensuring broad access for urban, suburban, and rural residents alike.

  2. Direct Relief for Patients, Especially Vulnerable Populations. By eliminating deductibles and coinsurance for COVID-19 antivirals, the legislation most directly benefits people at higher risk of severe illness (such as the elderly, immunocompromised, and low-income New Yorkers), removing financial barriers to potentially life-saving treatment.

  3. Coordination with Existing Free/Discount Programs. Insurers can require patients to use manufacturer or government assistance programs first if available, which helps control costs for the state and insurers and may reduce potential for duplicative spending—while still guaranteeing that no resident pays out-of-pocket for these medicines.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients with COVID-19

    Individuals who contract COVID-19 and are prescribed antiviral therapeutics will directly benefit from capped or eliminated out-of-pocket costs, making treatment more accessible.

  • Health Insurance Companies

    Insurers offering prescription drug coverage will need to adjust policies and administrative processes to comply with new requirements, potentially affecting their cost structures and claims handling.

  • Healthcare Providers

    Doctors and other licensed prescribers may see increased patient access and adherence to recommended COVID-19 treatments, as financial barriers are reduced or removed.

  • Low-Income and Vulnerable Populations

    Medicaid recipients and those relying on government or manufacturer patient assistance programs will have clearer, standardized access to COVID-19 antivirals without cost, which could improve health equity.

Headline styles

Cap COVID Antiviral Costs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Erik Bottcher

Senator · Senate District 47

Chair, Cities 1

No co-sponsors yet.

History

  1. Referred to insurance

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

10136

IN SENATE

April 30, 2026

Introduced by Sen. BOTTCHER -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 42 to read as follows:

(42) (A) Every policy that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(B) Coverage under this paragraph shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.

§ 2. Subsection (k) of section 3221 of the insurance law is amended by adding a new paragraph 24 to read as follows:

(24) (A) Every group or blanket policy delivered or issued for delivery in this state that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(B) Coverage under this paragraph shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD07443-02-6

§ 3. Section 4303 of the insurance law is amended by adding a new subsection (yy) to read as follows:

(yy) (1) Every contract issued by a medical expense indemnity corporation, a hospital service corporation, or a health service corporation that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(2) Coverage under this subsection shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this subsection.

§ 4. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (oo) to read as follows:

(oo) (i) antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(ii) coverage under this paragraph shall be provided at no cost to the insured, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.

§ 5. This act shall take effect on the first day of January next succeeding the date on which it shall have become a law and shall apply to all policies and contracts issued, renewed, modified, altered, or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics

Summary of provisions

Section one adds a new paragraph to section 3216 of the insurance law requiring individual insurance policies that provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.

Section two adds a new paragraph to section 3221 of the insurance law requiring group insurance policies that provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.

Section three adds a new paragraph to section 4303 of the insurance law requiring hospital service corporations or health service corporations insurance policies that provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.

Section four adds a new paragraph to section 365-a of the social services law Medicaid in New York State to provide coverage for prescription drugs to cover oral antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the insured.

Justification

Oral antiviral therapeutics can save the life of someone with COVID-19, having been shown to reduce the rate of serious illness and death from COVID by as much as 89 percent. Yet a 2023 study of by the National Institutes of Health found that only 9.7 percent of 1.3 million high- risk patients eligible for an oral antiviral prescription had actually received it (Hansen et al). These numbers can vary by demographic group, with a December 2023 study by researchers at the City University of New York finding that eligible Black and low-income patients take these medications at even lower rates (Shen et al).

Many oral antiviral therapeutics have shifted into the commercial market for distribution, at times costing more than $1,300 for a single prescription. Though federal and private cost assistance programs prom- ise to offset or eliminate the cost of a COVID-19 antiviral prescription through 2024, many insured New Yorkers could still face out-of-pocket costs that pose a barrier to uptake.

To ensure cost does not prohibit any New Yorker from taking life-saving medication to treat COVID-19, this bill would require private insurers and Medicaid to cover the full cost of COVID-19 oral antiviral therapeu- tics for eligible New Yorkers with a prescription.

Legislative history

This bill was introduced by then-Senator Brad Hoylman-Sigal in 2025 (Senate Bill S6925).

S.8637B (2023-2024): Passed Senate, Died in Assembly

Fiscal implications

None to New York State.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.